{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:09:09Z","timestamp":1776276549208,"version":"3.50.1"},"reference-count":48,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,12,10]]},"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the profile of patients with ankylosing spondylitis (AS) treated with infliximab in Canadian routine care and to assess the effectiveness and safety of infliximab in real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>46 primary care rheumatology practices across Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>303 biological-na\u00efve patients with AS or patients previously treated with a biological for &lt;6\u2005months and who were eligible for infliximab treatment as per routine care within the Biologic Treatment Registry Across Canada (BioTRAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Not applicable (non-interventional study).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes<\/jats:title>\n                    <jats:p>Effectiveness was assessed with changes in disease parameters (AS Disease Activity Score (ASDAS), Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Health Assessment Questionnaire Disease Index (HAQ-DI), physician global assessment of disease activity (MDGA), patient global disease activity (PtGA), back pain, C-reactive protein, erythrocyte sedimentation rate (ESR), morning stiffness). Safety was assessed with the incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 303 patients included, 44.6% were enrolled in 2005\u20132007 and 55.4% in 2008\u20132013. Patients enrolled in 2005\u20132007 had significantly higher MDGA and ESR at baseline while all other disease parameters examined were numerically higher with the exception of PtGA. Treatment with infliximab significantly (p&lt;0.001) improved all disease parameters over time in both groups. At 6\u2005months, 56% and 31% of patients achieved clinically important (change\u22651.1) and major (change\u22652.0) improvement in ASDAS, respectively; at 48\u2005months, these proportions increased to 75% and 50%, respectively. Among patients unemployed due to disability at baseline, 12.1% returned to work (mean Kaplan-Meier (KM)-based time=38.8\u2005months). The estimated retention rate at 12 and 24\u2005months was 78.3% and 60.1%, respectively. The profile and incidence of AEs were comparable to data previously reported for tumour necrosis factor-\u03b1 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Characteristics of patients with AS at infliximab initiation changed over time towards lower disease activity and shorter disease duration. Infliximab treatment significantly reduced disease activity independent of treatment initiation year, although patients enrolled in recent years achieved lower disease activity over 48\u2005months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT00741793.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009661","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T22:43:02Z","timestamp":1459896182000},"page":"e009661","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis"],"prefix":"10.1136","volume":"6","author":[{"given":"Proton","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Medicine & Rheumatology, Memorial University, St. John's, Newfoundland, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[{"name":"Institut de Rhumatologie de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G","family":"Bensen","sequence":"additional","affiliation":[{"name":"St. Joseph's Hospital, Hamilton, Ontario, Canada"},{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Khraishi","sequence":"additional","affiliation":[{"name":"Memorial University of Newfoundland, St. John's, Newfoundland, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chow","sequence":"additional","affiliation":[{"name":"Credit Valley Rheumatology, Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Zummer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Shaikh","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqbool","family":"Sheriff","sequence":"additional","affiliation":[{"name":"Nanaimo Regional General Hospital, Nanaimo, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Dixit","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton","family":"Sholter","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliofotisti","family":"Psaradellis","sequence":"additional","affiliation":[{"name":"JSS Medical Research Inc., St-Laurent, Quebec, Canada"},{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S","family":"Sampalis","sequence":"additional","affiliation":[{"name":"JSS Medical Research Inc., St-Laurent, Quebec, Canada"},{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Letourneau","sequence":"additional","affiliation":[{"name":"Janssen Inc. Medical Affairs, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen J","family":"Lehman","sequence":"additional","affiliation":[{"name":"Janssen Inc. Medical Affairs, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Nantel","sequence":"additional","affiliation":[{"name":"Janssen Inc. Medical Affairs, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"JSS Medical Research Inc., St-Laurent, Quebec, Canada"},{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Otawa","sequence":"additional","affiliation":[{"name":"Janssen Inc. Medical Affairs, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Janssen Inc. Medical Affairs, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,4,5]]},"reference":[{"key":"2025121604235678000_6.4.e009661.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"2025121604235678000_6.4.e009661.2","first-page":"79","article-title":"[Ankylosing spondylitis]","volume":"151","author":"Braun","year":"2009","journal-title":"MMW Fortschr Med"},{"key":"2025121604235678000_6.4.e009661.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-12-200206180-00011"},{"key":"2025121604235678000_6.4.e009661.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_3.iii8"},{"key":"2025121604235678000_6.4.e009661.5","unstructured":"The Arthritis Society. Ankylosing spondylitis. The Arthritis Society, 2013."},{"key":"2025121604235678000_6.4.e009661.6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/berh.2002.0244","article-title":"Ankylosing spondylitis: what is the cost to society, and can it be reduced?","volume":"16","author":"Boonen","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025121604235678000_6.4.e009661.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.732"},{"key":"2025121604235678000_6.4.e009661.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh271"},{"key":"2025121604235678000_6.4.e009661.9","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#"},{"key":"2025121604235678000_6.4.e009661.10","first-page":"S23","article-title":"Socioeconomic consequences of ankylosing spondylitis","volume":"20","author":"Boonen","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2025121604235678000_6.4.e009661.11","first-page":"721","article-title":"Employment across chronic inflammatory rheumatic diseases and comparison with the general population","volume":"32","author":"Mau","year":"2005","journal-title":"J Rheumatol"},{"key":"2025121604235678000_6.4.e009661.12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<424::AID-ART361>3.0.CO;2-7"},{"key":"2025121604235678000_6.4.e009661.13","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025121604235678000_6.4.e009661.14","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856020-00006"},{"key":"2025121604235678000_6.4.e009661.15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1517\/14712598.5.8.1095","article-title":"Infliximab for the treatment of ankylosing spondylitis","volume":"5","author":"Rudwaleit","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"2025121604235678000_6.4.e009661.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21790"},{"key":"2025121604235678000_6.4.e009661.17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"2025121604235678000_6.4.e009661.18","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J Rheumatol"},{"key":"2025121604235678000_6.4.e009661.19","first-page":"1605","article-title":"Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis","volume":"28","author":"Stone","year":"2001","journal-title":"J Rheumatol"},{"key":"2025121604235678000_6.4.e009661.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014258"},{"key":"2025121604235678000_6.4.e009661.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.6.428"},{"key":"2025121604235678000_6.4.e009661.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.10883"},{"key":"2025121604235678000_6.4.e009661.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032441"},{"key":"2025121604235678000_6.4.e009661.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064543"},{"key":"2025121604235678000_6.4.e009661.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem084"},{"key":"2025121604235678000_6.4.e009661.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0727-6"},{"key":"2025121604235678000_6.4.e009661.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068734"},{"key":"2025121604235678000_6.4.e009661.28","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink","year":"2006","journal-title":"J Rheumatol"},{"key":"2025121604235678000_6.4.e009661.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440508"},{"key":"2025121604235678000_6.4.e009661.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025121604235678000_6.4.e009661.31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.22290","article-title":"Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicentre prospective observational registry","volume":"66","author":"Thorne","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121604235678000_6.4.e009661.32","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025121604235678000_6.4.e009661.33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00296-010-1599-7","article-title":"Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP","volume":"32","author":"Bodur","year":"2012","journal-title":"Rheumatol Int"},{"key":"2025121604235678000_6.4.e009661.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933"},{"key":"2025121604235678000_6.4.e009661.35","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E"},{"key":"2025121604235678000_6.4.e009661.36","first-page":"247","article-title":"Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice","volume":"26","author":"Haibel","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2025121604235678000_6.4.e009661.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270301"},{"key":"2025121604235678000_6.4.e009661.38","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm"},{"key":"2025121604235678000_6.4.e009661.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206616"},{"key":"2025121604235678000_6.4.e009661.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.741"},{"key":"2025121604235678000_6.4.e009661.41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060293"},{"key":"2025121604235678000_6.4.e009661.42","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2010.487838"},{"key":"2025121604235678000_6.4.e009661.43","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0297"},{"key":"2025121604235678000_6.4.e009661.44","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.5.429"},{"key":"2025121604235678000_6.4.e009661.45","first-page":"289","article-title":"Costs and quality of life of patients with ankylosing spondylitis in Canada","volume":"33","author":"Kobelt","year":"2006","journal-title":"J Rheumatol"},{"key":"2025121604235678000_6.4.e009661.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.20419"},{"key":"2025121604235678000_6.4.e009661.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025130"},{"key":"2025121604235678000_6.4.e009661.48","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:07Z","timestamp":1765887847000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,5]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/bmjopen-2015-009661"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009661","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}